GLOW1 and GLOW2 – Primary Endpoint met . Zenkuda established superiority in ≥2 -step improvement in Diabetic Retinopathy Severity Score (DRSS) GLOW1: Sham (n=125); Zenkuda (n=128). GLOW2: Sham (n=125); Zenkuda (n=130); Week 48 (LOCF) represents the last available observation while on randomized treatment, within the Week 48 visit window. Note: Weighted percentages are based on weighted average of observed estimates across strata using CMH weights. p-values are based on the difference in response rates 3.3% 62.5% 0% 25% 50% 75% Sham Zenkuda Proportion of patients with ≥2 -Step improvement in DRSS from Baseline to Week 48 p<0.0001 GLOW1 GLOW2 1.4% 41.1% 0% 25% 50% 75% Sham Zenkuda p<0.0001 4 Figure 2